Back Tuberculosis

EACS 2015: 3-Month Isoniazid/Pyrazinamide Regimen Prevents TB in People with HIV

A daily 3-month regimen of isoniazid and pyrazinamide is just as effective at preventing the development of active tuberculosis (TB) in people living with HIV as a 6-month course of isoniazid alone, according to findings from a Russian study presented by Zinaida Zagdyn at the 15th European AIDS Conference last week in Barcelona.

alt

Read more:

IAS 2015: Presumptive Treatment of TB in Advanced HIV No Better than ART and Isoniazid

Giving treatment for tuberculosis (TB) to all people with very advanced HIV disease at the time they start antiretroviral therapy (ART), before a laboratory diagnosis of TB -- so-called empiric treatment -- does not reduce the risk of death compared to giving ART and isoniazid preventive therapy, according to findings presented by Mina Hosseinipour at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this week in Vancouver.

alt

Read more:

World TB Day: Find, Treat, and Cure Tuberculosis

In recognition of World TB Day on March 24, organizations released their latest figures on tuberculosis in the U.S. and worldwide and called for more action to improve access to testing, care, and treatment, while 2 recent studies offered promise for shorter therapy.

March 24 Is World TB Day

PaMZ Combination Regimen Shortens and Simplifies Tuberculosis Treatment

CROI 2015: High-Dose Rifampin Shortens Time to Tuberculosis Clearance

3/24/15

alt

 

 

 

March 24 Is World TB Day

March 24 is World TB Day, an opportunity to raise awareness about tuberculosis (TB) and the need for expanded testing and treatment worldwide. The latest data from the CDC indicate that TB cases in the U.S. have reached an all-time low of 9412 cases, but the decline has slowed. Globally, the World Health Organization (WHO) estimates that 9 million people fell ill with TB -- including 480,000 with multidrug-resistant TB -- and 1.5 million people died from the disease in 2013. An estimated 1.1 million people living with HIV were coinfected with TB in 2013, and TB is among the leading causes of death for HIV-positive people, accounting for 25% of all HIV-related deaths.

alt

Read more:

PaMZ Combination Regimen Shortens and Simplifies Tuberculosis Treatment

An oral regimen combining the new drug pretomanid (PA-824) with the older moxifloxacin and pyrazinamide -- known as PaMZ for short -- has the potential to reduce the duration of treatment for drug-sensitive and even some drug-resistant tuberculosis (TB), according to findings from a study published in the March 17 online edition The Lancet. Nearly twice as many patients treated with the PaMZ regimen had undetectable TB in cultured sputum compared to those taking standard therapy.

alt

Read more: